Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03050554
Recruitment Status : Active, not recruiting
First Posted : February 13, 2017
Last Update Posted : March 20, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Andrew Sharabi, University of California, San Diego

Brief Summary:

The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).

Avelumab is considered experimental because it is not approved by the United States (U.S.) Food and Drug Administration (FDA) for the treatment of cancer. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies are made to recognize, target and bind to specific proteins on the cells that make up your tissues. Avelumab is designed to block the interaction between PD-1, a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer.

Stereotactic Body Radiation Therapy (SBRT) is a type of radiation that uses precise targeting to deliver a high dose of radiation to the tumor over a short period of time. A positioning cushion such as Vac-lok will be used during radiation treatment that is custom made. This custom mold forms to the contours of the subjects body to allow for proper positioning comfort and stability.


Condition or disease Intervention/treatment Phase
Early Stage Non-Small Cell Lung Cancer Drug: Avelumab Radiation: SBRT Phase 1 Phase 2

Detailed Description:
This is a single arm open label Phase I/II study that will consist of two parts. In Phase I, investigators will assess the safety and tolerability of SBRT combined with Avelumab. In Phase II, investigators will determine whether SBRT combined with Avelumab improves relapse free survival. Subjects with Stage I NSCLC who are not undergoing surgical resection will be candidates for enrollment. Subjects will receive definitive stereotactic body radiation (SBRT) in 4-5 fractions combined with concurrent and adjuvant Avelumab at 10mg/kg for a total of 6 cycles. Subjects will be evaluated for safety as measured by the occurrence of adverse events, serious adverse events, and laboratory abnormalities. Three blood draws will be obtained to analyze anti-tumor immune responses and immune correlates.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : October 26, 2017
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Avelumab

Arm Intervention/treatment
Experimental: SBRT+Avelumab

SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

Drug: Avelumab
Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

Radiation: SBRT
SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)




Primary Outcome Measures :
  1. Safety and tolerability of definitive SBRT combined with concurrent and adjuvant Avelumab in patients with early stage NSCLC (Measured Via Adverse Events). [ Time Frame: 6 months ]
    Measured Via Adverse Events

  2. Relapse free survival (RFS) [ Time Frame: 3 years ]
    Relapse-Free Survival (RFS) is defined as the time from starting treatment to the time of first documented tumor progression or death due to any cause, whichever occurs first. Death is considered as an event here.


Secondary Outcome Measures :
  1. Loco-regional control (LRC) [ Time Frame: 3 years ]
    Locoregional Control (LRC) is defined as the time from starting treatment until local and/or regional relapse is documented

  2. Overall survival in patients after completion of SBRT in combination with Avelumab [ Time Frame: 3 years ]
    Overall survival in patients is defined as the time from after completion of SBRT in combination with Avelumab



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Tumor(s) to be treated is(are) ≤ 5.0 cm or ≤250 cm3
  • Stage I NSCLC and is deemed medically inoperable or refuses surgical resection.
  • Life expectancy ≥ 9 months.
  • Acceptable organ and marrow function

Exclusion Criteria:

  • Prior organ transplantation, including allogeneic stem cell transplantation
  • Significant acute or chronic infections including:

    • Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
    • Known history of HBV or HCV
  • Active autoimmune disease

    • Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
    • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
    • Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable
  • Current use of immunosuppressive medication, EXCEPT for the following:

    • intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  • Cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
  • Known severe hypersensitivity reactions to monoclonal antibodies any history of anaphylaxis, or uncontrolled asthma
  • Pregnancy or lactation
  • Known alcohol or drug abuse
  • Prior radiotherapy to the treatment site(s).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050554


Locations
Layout table for location information
United States, California
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
United States, South Dakota
Sanford Health
Sioux Falls, South Dakota, United States, 57104
Sponsors and Collaborators
Andrew Sharabi
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Andrew Sharabi, M.D., Ph.D. University of California, San Diego

Layout table for additonal information
Responsible Party: Andrew Sharabi, Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT03050554     History of Changes
Other Study ID Numbers: 161591
First Posted: February 13, 2017    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Andrew Sharabi, University of California, San Diego:
cancer
Non-Small Cell Lung Cancer
SBRT
Avelumab
Stereotactic Body Radiation Therapy
radiation
NSCLC
PD-1
PD-L1
Immunotherapy
Lung

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs